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Background: Trastuzumab was licensed for adjuvant therapy in
early breast cancer (EBC) in the UK in 2006. The objectives of this
multicentre audit were to determine the incidence of HER2+
breast cancers, proportion of HER2+ EBC women who received
Trastuzumab and ascertain reasons why some HER2+ patients
did not receive Trastuzumab.
Methods: Data collected for all invasive breast cancers diag-
nosed at seven UK centres over 18-months from 2007 onwards.
All HER2+ cancers diagnosed by a combination of IHC and FISH
identified using each centre’s database. Case records checked
and reasons noted if they had not received Trastuzumab.
Results: Patients (4488) diagnosed with invasive breast cancer.
645 (14%) were HER2+ cancers, 523 being EBCs. 326 (62%) HER2+
EBCs received Trastuzumab.
Reasons for not receiving Trastuzumab n = 197(%)
Tumour 610 mm, node negative 65(33)
Small node negative tumours (11–20 mm) 18(9)
Age 42(21)
Comorbidities 27(13)
Therapy refused 28(14)
Other reasons 17(9)
Conclusions: Incidence of HER2+ breast cancers is 14%, majority
being EBCs (81%). Only 62% of the HER2+ EBC patients received
Trastuzumab. Whilst the commonest reason for not receiving
Trastuzumab is small node negative tumours (which is compatible
with UK guidelines), an equal number of patients potentially
missed optimal therapy for reasons not noted in the guidelines.
Recent studies havedemonstrated that beingHER2+ is a significant
risk factor for relapse in patients previously perceived to be at low
risk and no HER2+ patient should now be considered low risk.1
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Objective: Of the 49,452 breast cancers diagnosed in the UK in
2006, 25,049 (51%) were diagnosed symptomatically in patients
aged 50 and over. This study compares the nature and treatment
of symptomatic invasive cancers in patients aged 50–69 and 70
years or over (‘elderly’).
Methods: Data were extracted from national audit databases
and from the merged cancer registry database linked to HES.
Results: 84% of Patients aged 50–69 had surgery recorded
compared with 55% of patients aged 70 or over. Surgery rates
increased to 79% in ‘elderly’ patients known to be ER negative.
‘Elderly’ patients were more likely to have a mastectomy (61%
versus 50%). For surgically treated tumours, prognostic factors
were similar in both groups: node positivity: 54% in 50–69 ver-
sus 50% in ‘elderly’, ER status (73% ER positive in 50–69 versus
77% in ‘elderly’) and grade (52% Grade 1 or 2 in 50–69 versus
59% in ‘elderly’). For cases with adjuvant therapy data avail-
able, radiotherapy after conserving surgery was slightly lower
in the ‘elderly’ (87% versus 94%), chemotherapy for node posi-
tive patients was much lower in the ‘elderly’ (21% versus 75%)
and more ‘elderly’ patients received hormone therapy (90%
versus 83%).
Conclusion: ‘Elderly’ patients were less likely to receive surgery
or chemotherapy. Patient choice, the presence of co-morbidities,
lack of evidence on the relative risks/benefits of adjuvant therapy
or reduced access to surgery for older patients are factors which
might explain the differential treatment of these patients.
doi:10.1016/j.ejcsup.2010.06.041
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Background: Breast cancer relative survival (BCRS) tends to be
poorer in older women, but the reasons for this are not clear.
We examined the influence of patient and tumour characteristics,
and treatment on BCRS to see if these could explain the age spe-
cific effects.
Methodology: Data for 14,048 female breast cancer patients
diagnosed from 1999 to 2007 aged 50 years or over were obtained
from the Eastern Cancer Registration and Information Centre. We
estimated relative 5- and 10-year survival for patients in four age
groups (50–69, 70–74, 75–79, and 80+). We also modelled relative
excess mortality rate (REM) adjusting for potential confounders.
Covariates included in the analysis were age, TNM stage, histo-
logic grade, ER status, mode of detection, volume at hospital of
diagnosis, and treatment (surgery, radiotherapy, chemotherapy
and hormonal therapy.
Results: Median follow-up time was 4.7 years. Relative 5-
year survival was 90%, 81%, 76% and 68% for patients aged
50–69, 70–74, 75–79 and 80+, respectively. Corresponding rela-
tive 10-year survival was 84%, 77%, 66% and 60%. Similar pat-
terns were seen for both ER+ and ER and for low and high
volume hospitals.
Unadjusted REM was 1.95, 2.86 and 4.30 for patients aged 70–
74, 75–79 and 80+, respectively (50–69 reference). These were
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attenuated after adjusting for confounders (REM – 1.50, 1.38 and
1.27).
Conclusion: We confirmed poorer BCRS in older women in our
region. This was partially explained by known prognostic factors.
Further research is needed to determine whether biological differ-
ences or sub-optimal management can explain the residual
excess mortality.
doi:10.1016/j.ejcsup.2010.06.042
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Introduction: Biology of breast cancer appears to change with
age. Most studies are small/from multiple centres limiting their
importance.
Methods: From 1973 to 2009, 2000+ EPCs were managed in
Nottingham. Oestrogen receptor (ER) was assessed by immuno-
histochemistry (giving an H-score) on core biopsy for all
patients. A total of 831 patients had primary surgery and 575
had good quality tumour samples available for tissue micro-
array analysis.
Results: Comparing these 831 patients with a younger (<70
years) series (N = 1809), expression of ER (p < 0.001), p53, HER4,
CK14, bcl2 (p < 0.000) and CK 17 (p < 0.05) was found to increase
with age, while reverse was seen with CK 7/8 (p < 0.002), ki67
and E-Cadherin (p < 0.000). No change was observed in PR, HER2,
CK5/6, CK19 and MUC1 expression.
At 66-month median follow-up, for those who did not receive
adjuvant systemic therapy (N = 306), tumour size (p < 0.042), grade
(p < 0.046), axillary stage (p < 0.000) and PR (p < 0.017) were found
to be independent prognostic factors.
At 49-month median follow-up, for patients with ER+ (H-
scoreP 50) tumours, those with H-scoreP 250 had equivalent
5-year breast cancer specific survival (BCSS) regardless of primary
treatment (surgery vs primary endocrine therapy (PET) 95% ver-
sus 93%, p = 0.715). For patients on PET, all those with H-
scoreP 250 achieved clinical benefit as compared to 11 patients
with H-score < 250 who progressed, at 6 months (p < 0.03), the for-
mer also had better BCSS (p < 0.01).
Conclusion: The pattern suggests a less aggressive tumour phe-
notype with advancing age. The ER H-score appears as an excel-
lent surrogate for clinical outcome for ER+ EPCs. It is available
at diagnosis and has a great value in guiding discussion of thera-
peutic options.
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Introduction: MiRNAs exert their regulatory effect on gene
expression by binding to the 30 untranslated region (UTR) of target
mRNAs. The let-7 miRNA family are global genetic regulators crit-
ically important for controlling oncogene expression (e.g. KRAS).
Dysregulated let-7 expression is associated with many malignan-
cies including breast cancer, and it is hypothesized that defective
interaction between let-7 and its target KRAS underpins this asso-
ciation and oncogenesis. We hypothesized that a single nucleo-
tide polymorphism (SNP) in the let-7-binding site in KRAS
disrupts let-7 regulation of the oncogene and thus predisposes
to breast cancer.
Methods: A population analysis of the association of the KRAS
variant and breast cancer was performed on a cohort of 1010
breast cancer patients and 1497 age-matched healthy controls.
Genomic DNA isolated from all participants was amplified using
PCR assays designed specifically to identify the T (wild type) or
G (variant) allele. Genotyping results were correlated with
patients’ clinicopathological parameters.
Results: The KRAS variant was present in 15% of all breast can-
cer patients, compared with baseline prevalence of <7%. In partic-
ular the KRAS-variant predicted a significantly increased risk of
developing triple negative breast cancer in premenopausal
women (OR = 4.78, CI = 1.71–13.38, p = 0.015), and patients with
the variant allele were significantly more likely to present with
advanced stage disease (p = 0.03).
Conclusion: These seminal findings suggest that the KRAS-var-
iant acts as a genetic marker of risk for developing triple negative
breast cancer. Predicting risk for this subtype is critically impor-
tant, to permit early screening and intervention for ‘at-risk’
individuals.
doi:10.1016/j.ejcsup.2010.06.044
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Background: Genome-wide association studies, together with
analyses of specific candidate polymorphisms, have identified a
number of low-penetrance breast cancer susceptibility loci. Infor-
mation is scarce about the combined effects on breast cancer
incidence of these genetic variants and of environmental factors
(reproductive, behavioural, and anthropometric risk factors for
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